Study on Ginger as a Treatment for Stress and Anxiety Comparing With Diazepam
DOI:
https://doi.org/10.54361/;JMR.20.2.83Keywords:
Ginger, Behavior, Stress, Anxiety, DiazepamAbstract
Background: The psychological anxiety is considered one of the most significant animals of the modern era. The most common causes natural indictors that lead to tension, severe stress and un-desirable mental problems or disease are stress Anxiety problems or disease that considered as most frequently appearing as disorders. Anxiety disease is diagnosing as condition that showed or indicate to serious and severe or pathological case as the essential disturbance emotional tone. Aim: In this study, ginger was tested in both diluted and concentrated forms suspension to evaluate its potential to alleviate psychological anxiety. it was compared against a positive control (diazepam) and negative control (water). To determine the anti-anxiety action of plant Ginger syrup extract. Diazepam is golden standard act as blocking or antagonized of stress and anxiety.Methodology: Experimental study was conducted in 2026. using animals albino mice and elevated plus-maze model (EPM) as a good standard technique for determined anti-anxiety behavior and stress inhibited. It is a validated and reliable measure of psychological anxiety, an animal's movement and crossing in an open area of elevated plus-maze indicates the absence of psychological anxiety, whereas its movement in an enclosed area indicates the presence of psychological anxiety.Results: This study, which relied on the use of ginger extract to reduce symptoms of anxiety like behavior and stress, because when treated animals with ginger lead to increased time spent and number of crossing and number of entries to open arms of elevated plus-maze instrument. clearly indicate or showed me that this extract is good and beneficial in stress management and reducing anxiety, especially after comparing it to golden standard Diazepam, the leading drug in this field. This clear results to important natural products as ginger extraction replace chemical substances.Conclusion: This experimental study using male albino mice as animals, was it is been done to appear possibility effects of plant Ginger extraction to inhibit stress and anxiety behavior by using elevated plus-maze technique. This experimental study, was indicate or observed clear antagonized or blocking action to stress and anxiety induced-like behavior by used plant ginger extract or suspension in safe compatible suitable concentration. These good results to important ginger natural substances replace chemical compounds.
Downloads
References
1. Adolphs R, Tranel D, Damasio AR. The human amygdala in social judgement. Nature. 1998;393:470-474.
2. Allen AM, Oldfield BJ, Giles ME, Paxinos G, McKinley MJ, Mendelsohn FAO. Localization of angiotensin receptors in the nervous system. In: Quirion R, Björklund A, Hökfelt T, editors. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier; 2000. P. 79-124.
3. Allen AM. Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension. 2002;39:275-280.
4. Arborelius L, Owens MJ, Plotsky PM. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1-12.
5. Averill DB, Diz DI. Angiotensin peptides and baroreflex control of sympathetic outflow: pathways and mechanisms of the medulla oblongata. Brain Res Bull. 2000;51:119-128.
6. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996. P. 399-427.
7. Bale TL, Contarino A, Smith GW. Mice deficient for corticotrophin-releasing hormone receptor-2 display anxiety-like behavior and are hypersensitive to stress. Nat Genet. 2000;24:410-414.
8. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59(Suppl 17):54-60.
9. Barbee JG. Mixed symptoms and syndromes of anxiety and depression: diagnostic, prognostic, and etiologic issues. Am J Psychiatry. 1998;10:15-29.
10. Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York: Guilford Press; 1998.
11. Barlow DH, Chorpita BF, Turovsky J. Fear, panic, anxiety, and disorders of emotion. In: Hope DA, editor. Perspectives on Anxiety, Panic, and Fear. Lincoln: University of Nebraska Press; 1996. P. 251-328.
12. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Ironside JW, Naylor RJ, et al. Angiotensin II inhibits Ach release from human temporal cortex: implications for cognition. Brain Res. 1990;507:341-343.
13. Barth SW, Gerstberger R. Differential regulation of angiotensinogen and AT1A receptor mRNA within the rat subfornical organ during dehydration. Mol Brain Res. 1999;64:151-164.
14. Bhattacharya SK, Mitra SK. Anxiolytic activity of Panax ginseng roots: an experimental study. J Ethnopharmacol. 1991;34:87-92.
15. Bhattacharya SK, Chakrabarti A, Sandler M, Glover V. Rat brain monoamine oxidase A and B inhibitory (tribulin) activity during drug withdrawal anxiety. Neurosci Lett. 1995;199:103-106.
16. Bhattacharya SK, Satyan KS. Experimental evaluation of psychotropic agents in rodents: I. Anxiety agents. Indian J Exp Biol. 1997;35:565-575.
17. Breiter HC, Etcoff NL, Whalen PJ, Kennedy WA, Rauch SL, Buckner RL, et al. Response and habituation of the human amygdala during visual processing of facial expression. Neuron. 1996;17:875-887.
18. Busto U, Sellers EM, Naranjo CA, Cappell HP, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315:654-659.
19. Chalmers DT, Lovenberg TW, DeSouza EB. Localization of novel corticotropin-releasing factor receptor (CRF-2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF-1 receptor mRNA expression. J Neurosci. 1995;15:6340-6350.
20. Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol. 1996;10:419-446.
21. Charney DS, Heninger GR, Redmond DE. Yohimbine-induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 1983;33(1):19-29.
22. Charron G, Laforest S, Gagnon C, Drolet G, Mouginot D. Acute sodium deficit triggers plasticity of the brain angiotensin type 1 receptor. FASEB J. 2002;16:610-612.
23. Chen QH, Toney GM. AT1-receptor blockade in the hypothalamic PVN reduces central hyperosmolality-induced renal sympathoexcitation. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1844-R1853.
24. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry. 1998;44:1264-1276.
25. Coplan JD, Pine DS, Papp LA, Gorman JM. A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotropin-releasing factor function in anxiety and affective disorders: the reduced growth hormone response to clonidine. Psychopharmacol Bull. 1997;33:193-204.
26. Costall B, Naylor RJ. Anxiolytic potential of 5-HT3 receptor antagonists. Pharmacol Toxicol. 1991;70:157-162.
27. Cui LN, Coderre E, Renaud LP. Glutamate and GABA mediate suprachiasmatic nucleus inputs to spinal-projecting paraventricular neurons. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1283-R1289.
28. Culman J, Unger T. Central tachykinins: mediators of defence reaction and stress reactions. Can J Physiol Pharmacol. 1995;73:885-891.
29. Davis M. Neurobiology of fear responses: the role of the amygdala. J Neuropsychiatry Clin Neurosci. 1997;9:382-402.
30. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
31. De Wardener HE. The hypothalamus and hypertension. Physiol Rev. 2001;81:1599-1658.
32. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signaling and function. Clin Sci. 2001;100:481-492.
33. Dumont EC, Rafrafi S, Laforest S, Drolet G. Involvement of central angiotensin receptors in stress. Neuroscience. 1999;93:877-884.
34. Eddy MF, Walbroehl GS. Recognition and treatment of obsessive-compulsive disorder. Am Fam Physician. 1998;57:1623-1634.
35. Edling OP, Gohlke M, Paul R, Rettig HM, Stauss UM. Physiology of the renin-angiotensin system. In: Schachter M, editor. ACE Inhibitors: Current Use and Future Prospects. London: Martin Dunitz; 1995. P. 3-48.
36. Fitts DA, Starbuck EM, Ruhf A. Circumventricular organs and Ang II-induced salt appetite: blood pressure and connectivity. Am J Physiol. 2000;279:R2277-R2286.
37. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev. 1998;78:583-686.
38. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol. 2002;438:1-14.
39. Gard PR, Haigh SJ, Cambursano PT, Warrington CA. Strain differences in the anxiolytic effects of losartan in the mouse. Pharmacol Biochem Behav. 2001;69:35-40.
40. Goddard AW, Charney DS. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 1996;58(Suppl 2):4-11.
41. Greenberg PE, Sisitsky T, Kessler RC. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427-435.
42. Griffiths CD, Morgan TO, Delbridge LM. Effects of combined administration of an ACE inhibitor and an angiotensin II receptor antagonist are prevented by high NaCl intake. J Hypertens. 2001;19:2087-2095.
43. Han X, Liu P, Zheng YY, et al. High-hydrostatic-pressure extract of ginger exerts anti-stress effects in immobilization-stressed rats. J Med Food. 2017;20(8):751-758.
44. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of fear-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984;327:1-5.
45. Hardy SG. Hypothalamic projections to cardiovascular centers of the medulla. Brain Res. 2001;894:233-240.
46. Hogg S. A review of the validity and variability of the elevated plus-maze animal model of anxiety. Pharmacol Biochem Behav. 1996;54:21-30.
47. Hoggs S (1996). Areview of the validity and variability of the elevated plus-maze animal model of anxiety. Pharmacol. Biochem. Behav., 54: 21-30.
48. Huang BS and Leenen FH (1999). Brain renin-angiotensin system and ouabain induced sympathetic hyperactivity and hypertension in Wistar rats. Hypertension, 34: 107-112.
49. Ingram RE, Miranda J, Segal ZV. Cognitive Vulnerability to Depression. New York: Guilford Press; 1998.
50. Ikvan Vliet IM, Westenberg HG and den Boer JA (1996). Effects of the 5HTIA recepror agonist flesinoxan in panic disorder. Psychopharmacology (Berl), 127(2): 174-180.
51. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev. 1991;12:118-134.
52. Kandel ER. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Am J Psychiatry. 1999;156:505-524.
53. Kaplan HI, Sadock BJ. Comprehensive Textbook of Psychiatry. 6th ed. Baltimore: Williams & Wilkins; 1995. P. 1244-1248.
54. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Post-traumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048-1060.
55. Kim JE, Kim YJ, Lee KW, et al. Network pharmacology-guided evaluation of ginger and cornelian cherry extracts against chronic depression and metabolic dysfunction in estrogen-deficient stressed rats. Nutrients. 2025;17(10):1687.
56. Nugroho AE, Hermawan A, Putri H, et al. Gingerols and shogaols of Zingiber officinale var. Sunti Valeton as potential allosteric agonists of human GABAA receptors by an in silico pharmacology approach. J Ethnopharmacol. 2024;319(Pt 1):117089.
57. Vargas-Castillo A, Puertollano MA, de Pablo MA, et al. Gingerol-enriched ginger extract effects on anxiety-like behavior in a neuropathic pain model via colonic microbiome-neuroimmune modulation. Nutrients. 2025;17(9):1543.
58. Van Vliet IM, Westenberg HGM, den Boer JA. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl). 1996;127(2):174-180.
59. Zhang L, Wang Y, Liu X, et al. 6-Gingerol exerts antidepressant effects through regulating the PPARγ signaling pathway. Eur J Pharmacol. 2025;988:177201.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Libyan Journal of Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
https://portal.issn.org/resource/ISSN/2413-6069
